Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1999 Sep;67(3):300–307. doi: 10.1136/jnnp.67.3.300

The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years

M Hely 1, J Morris 1, R Traficante 1, W Reid 1, D O'Sullivan 1, P Williamson 1
PMCID: PMC1736543  PMID: 10449550

Abstract

OBJECTIVES—To report on a 10 year follow up of patients with idiopathic Parkinson's disease, particularly with respect to mortality and the effect of early treatment with bromocriptine.
METHODS—The patients are from the 149 new patients recruited for a double blind, randomised study of low dose levodopa-carbidopa versus low dose bromocriptine. Patients were examined neurologically at least yearly. Neuropsychological examinations were performed at 0, 3, 5, and 10 years. Mortality and cause of death in these patients were compared with the Australian population using standardised mortality ratios (SMRs). Mortality and disease progression were compared by sex and treatment group. Predictors of death within 10 years, nursing home admission, and progression in Columbia score of ⩾20 points were examined by logistic regression analysis.
RESULTS—Thirteen patients were excluded as having atypical Parkinsonism and six were lost to follow up. All available patients have been followed up for 10 years. Fifty patients (38%) were dead by 10 years and 63 by the last follow up. The SMR was 1.58 for all patients (p<0.001). There was no significant difference in SMRs between the sexes. The mean duration of disease until death was 9.1 years. Parkinson's disease was thought to have contributed substantially to the death of 30 patients. The most common cause of death was pneumonia. Women progressed at a similar rate to men until 8 years, when the severity of their disease as measured by Hoehn and Yahr stage became greater (p<0.05). Older age of onset correlated with increased risk of death but the SMR was increased even in those aged <70 years (SMR 1.80, p=0.03). Early use of bromocriptine did not reduce mortality or slow progression of disease. One quarter of all patients had been admitted to nursing homes by 10 years. Only four patients were still employed.
CONCLUSIONS—Mortality in Parkinson's disease remains increased despite low dose levodopa-carbidopa therapy and no additional benefit was gained from early use of bromocriptine. Duration of disease was similar to that in the era before levodopa.



Full Text

The Full Text of this article is available as a PDF (121.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbeau A. Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol. 1976 May;33(5):333–338. doi: 10.1001/archneur.1976.00500050019004. [DOI] [PubMed] [Google Scholar]
  2. Ben-Shlomo Y., Churchyard A., Head J., Hurwitz B., Overstall P., Ockelford J., Lees A. J. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ. 1998 Apr 18;316(7139):1191–1196. doi: 10.1136/bmj.316.7139.1191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blin J., Dubois B., Bonnet A. M., Vidailhet M., Brandabur M., Agid Y. Does ageing aggravate parkinsonian disability? J Neurol Neurosurg Psychiatry. 1991 Sep;54(9):780–782. doi: 10.1136/jnnp.54.9.780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. CANTER G. J., DE LA TORRE R., MIER M. A method for evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis. 1961 Aug;133:143–147. doi: 10.1097/00005053-196108000-00010. [DOI] [PubMed] [Google Scholar]
  5. Chió A., Magnani C., Tolardo G., Schiffer D. Parkinson's disease mortality in Italy, 1951 through 1987. Analysis of an increasing trend. Arch Neurol. 1993 Feb;50(2):149–153. doi: 10.1001/archneur.1993.00540020027012. [DOI] [PubMed] [Google Scholar]
  6. Clarke C. E. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord. 1995 May;10(3):250–256. doi: 10.1002/mds.870100303. [DOI] [PubMed] [Google Scholar]
  7. Curtis L., Lees A. J., Stern G. M., Marmot M. G. Effect of L-dopa on course of Parkinson's disease. Lancet. 1984 Jul 28;2(8396):211–212. doi: 10.1016/s0140-6736(84)90493-8. [DOI] [PubMed] [Google Scholar]
  8. Diamond S. G., Markham C. H., Hoehn M. M., McDowell F. H., Muenter M. D. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology. 1990 May;40(5):763–766. doi: 10.1212/wnl.40.5.763. [DOI] [PubMed] [Google Scholar]
  9. Diamond S. G., Markham C. H., Hoehn M. M., McDowell F. H., Muenter M. D. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol. 1987 Jul;22(1):8–12. doi: 10.1002/ana.410220105. [DOI] [PubMed] [Google Scholar]
  10. Ebmeier K. P., Calder S. A., Crawford J. R., Stewart L., Besson J. A., Mutch W. J. Parkinson's disease in Aberdeen: survival after 3.5 years. Acta Neurol Scand. 1990 Apr;81(4):294–299. doi: 10.1111/j.1600-0404.1990.tb01558.x. [DOI] [PubMed] [Google Scholar]
  11. Fearnley J. M., Lees A. J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991 Oct;114(Pt 5):2283–2301. doi: 10.1093/brain/114.5.2283. [DOI] [PubMed] [Google Scholar]
  12. Goetz C. G., Stebbins G. T. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology. 1995 Apr;45(4):669–671. doi: 10.1212/wnl.45.4.669. [DOI] [PubMed] [Google Scholar]
  13. Goetz C. G., Tanner C. M., Stebbins G. T., Buchman A. S. Risk factors for progression in Parkinson's disease. Neurology. 1988 Dec;38(12):1841–1844. doi: 10.1212/wnl.38.12.1841. [DOI] [PubMed] [Google Scholar]
  14. Golbe L. I. Young-onset Parkinson's disease: a clinical review. Neurology. 1991 Feb;41(2 ):168–173. doi: 10.1212/wnl.41.2_part_1.168. [DOI] [PubMed] [Google Scholar]
  15. Gorell J. M., Johnson C. C., Rybicki B. A. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology. 1994 Oct;44(10):1865–1868. doi: 10.1212/wnl.44.10.1865. [DOI] [PubMed] [Google Scholar]
  16. Hely M. A., Morris J. G., Reid W. G., O'Sullivan D. J., Williamson P. M., Broe G. A., Adena M. A. Age at onset: the major determinant of outcome in Parkinson's disease. Acta Neurol Scand. 1995 Dec;92(6):455–463. doi: 10.1111/j.1600-0404.1995.tb00480.x. [DOI] [PubMed] [Google Scholar]
  17. Hely M. A., Morris J. G., Reid W. G., O'Sullivan D. J., Williamson P. M., Rail D., Broe G. A., Margrie S. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):903–910. doi: 10.1136/jnnp.57.8.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  19. Hughes A. J., Daniel S. E., Kilford L., Lees A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–184. doi: 10.1136/jnnp.55.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Jankovic J., McDermott M., Carter J., Gauthier S., Goetz C., Golbe L., Huber S., Koller W., Olanow C., Shoulson I. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990 Oct;40(10):1529–1534. doi: 10.1212/wnl.40.10.1529. [DOI] [PubMed] [Google Scholar]
  21. Jansson B., Jankovic J. Low cancer rates among patients with Parkinson's disease. Ann Neurol. 1985 May;17(5):505–509. doi: 10.1002/ana.410170514. [DOI] [PubMed] [Google Scholar]
  22. Joseph C., Chassan J. B., Koch M. L. Levodopa in Parkinson disease: a long-term appraisal of mortality. Ann Neurol. 1978 Feb;3(2):116–118. doi: 10.1002/ana.410030205. [DOI] [PubMed] [Google Scholar]
  23. Kuroda K., Tatara K., Takatorige T., Shinsho F. Effect of physical exercise on mortality in patients with Parkinson's disease. Acta Neurol Scand. 1992 Jul;86(1):55–59. doi: 10.1111/j.1600-0404.1992.tb08054.x. [DOI] [PubMed] [Google Scholar]
  24. Kurtzke J. F., Murphy F. M. The changing patterns of death rates in parkinsonism. Neurology. 1990 Jan;40(1):42–49. doi: 10.1212/wnl.40.1.42. [DOI] [PubMed] [Google Scholar]
  25. Lee C. S., Schulzer M., Mak E. K., Snow B. J., Tsui J. K., Calne S., Hammerstad J., Calne D. B. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain. 1994 Jun;117(Pt 3):501–507. doi: 10.1093/brain/117.3.501. [DOI] [PubMed] [Google Scholar]
  26. Lilienfeld D. E., Chan E., Ehland J., Godbold J., Landrigan P. J., Marsh G., Perl D. P. Two decades of increasing mortality from Parkinson's disease among the US elderly. Arch Neurol. 1990 Jul;47(7):731–734. doi: 10.1001/archneur.1990.00530070019005. [DOI] [PubMed] [Google Scholar]
  27. Louis E. D., Marder K., Cote L., Tang M., Mayeux R. Mortality from Parkinson disease. Arch Neurol. 1997 Mar;54(3):260–264. doi: 10.1001/archneur.1997.00550150024011. [DOI] [PubMed] [Google Scholar]
  28. Maier Hoehn M. M. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm Suppl. 1983;19:253–264. [PubMed] [Google Scholar]
  29. Marttila R. J., Rinne U. K., Siirtola T., Sonninen V. Mortality of patients with Parkinson's disease treated with levodopa. J Neurol. 1977 Oct 7;216(3):147–153. doi: 10.1007/BF00313615. [DOI] [PubMed] [Google Scholar]
  30. Morens D. M., Davis J. W., Grandinetti A., Ross G. W., Popper J. S., White L. R. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology. 1996 Apr;46(4):1044–1050. doi: 10.1212/wnl.46.4.1044. [DOI] [PubMed] [Google Scholar]
  31. Olanow C. W., Hauser R. A., Gauger L., Malapira T., Koller W., Hubble J., Bushenbark K., Lilienfeld D., Esterlitz J. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol. 1995 Nov;38(5):771–777. doi: 10.1002/ana.410380512. [DOI] [PubMed] [Google Scholar]
  32. Pederzoli M., Girotti F., Scigliano G., Aiello G., Carella F., Caraceni T. L-dopa long-term treatment in Parkinson's disease: age-related side effects. Neurology. 1983 Nov;33(11):1518–1522. doi: 10.1212/wnl.33.11.1518. [DOI] [PubMed] [Google Scholar]
  33. Peterson G. M., Nolan B. W., Millingen K. S. Survey of disability that is associated with Parkinson's disease. Med J Aust. 1988 Jul 18;149(2):66, 69-70. doi: 10.5694/j.1326-5377.1988.tb120506.x. [DOI] [PubMed] [Google Scholar]
  34. Poewe W. H., Wenning G. K. The natural history of Parkinson's disease. Neurology. 1996 Dec;47(6 Suppl 3):S146–S152. doi: 10.1212/wnl.47.6_suppl_3.146s. [DOI] [PubMed] [Google Scholar]
  35. Przuntek H., Welzel D., Blümner E., Danielczyk W., Letzel H., Kaiser H. J., Kraus P. H., Riederer P., Schwarzmann D., Wolf H. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol. 1992;43(4):357–363. doi: 10.1007/BF02220609. [DOI] [PubMed] [Google Scholar]
  36. Rajput A. H., Offord K. P., Beard C. M., Kurland L. T. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology. 1987 Feb;37(2):226–232. doi: 10.1212/wnl.37.2.226. [DOI] [PubMed] [Google Scholar]
  37. Rajput A. H., Offord K. P., Beard C. M., Kurland L. T. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol. 1984 Sep;16(3):278–282. doi: 10.1002/ana.410160303. [DOI] [PubMed] [Google Scholar]
  38. Roos R. A., Jongen J. C., van der Velde E. A. Clinical course of patients with idiopathic Parkinson's disease. Mov Disord. 1996 May;11(3):236–242. doi: 10.1002/mds.870110304. [DOI] [PubMed] [Google Scholar]
  39. Shaw K. M., Lees A. J., Stern G. M. The impact of treatment with levodopa on Parkinson's disease. Q J Med. 1980;49(195):283–293. [PubMed] [Google Scholar]
  40. Treves T. A. Parkinson's disease mortality: preliminary report. Adv Neurol. 1990;53:411–415. [PubMed] [Google Scholar]
  41. Uitti R. J., Ahlskog J. E., Maraganore D. M., Muenter M. D., Atkinson E. J., Cha R. H., O'Brien P. C. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology. 1993 Oct;43(10):1918–1926. doi: 10.1212/wnl.43.10.1918. [DOI] [PubMed] [Google Scholar]
  42. Wermuth L., Stenager E. N., Stenager E., Boldsen J. Mortality in patients with Parkinson's disease. Acta Neurol Scand. 1995 Jul;92(1):55–58. doi: 10.1111/j.1600-0404.1995.tb00466.x. [DOI] [PubMed] [Google Scholar]
  43. Zumstein H., Siegfried J. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor. Eur Neurol. 1976;14(5):321–328. doi: 10.1159/000114756. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES